Investigators presented an interim analysis of the phase 3 ENLIGHTED trial of photodynamic therapy in patients with low-grade upper-tract urothelial cancer.

One-year incidence of psychosocial therapy initiation was 12.6 percent, while incidence of medication initiation was 2.8 percent ...

An artificial intelligence-based tool identifies patients with high-risk, nonmetastatic prostate cancer (PCa) who would most likely benefit from treatment intensification, an investigator reported at ...

The first trial of adjuvant platinum-based chemotherapy plus paclitaxel in patients with high-risk penile cancer provided some insights.

Phase 3 trial results suggest that adjuvant treatment with mitomycin and bacillus Calmette-Guérin (BCG) is as safe and effective as BCG alone for patients with high-risk non-muscle invasive bladder ...

Data from clinical trials have indicated that PSA is prognostic for outcomes, but little is known about real-world trends.

Rapid reduction of glucocorticoid (GC) doses to 7.5 mg/day or less within 6 months may not worsen renal outcomes or increase relapse in patients with proliferative lupus nephritis (LN), recent study ...

PARP inhibitors demonstrate synergy with radiation, so investigators tested the efficacy and safety of olaparib plus radium-223 in patients with mCRPC and bone metastases in a phase 2 trial.

Medical AI tools for clinicians and patients have advantages and disadvantages, including implicit bias in triage and virtual urgent care.

AMPLITUDE is the “first trial to show efficacy for the combination of inhibition of PARP and the androgen receptor pathway in metastatic, castration-sensitive prostate cancer with alteration of genes ...

The number of data breaches affecting protected health information increased from 216 in 2010 to 566 in 2024. The number of health care data breaches that compromised protected health information ...